Table 4.

AG MGMT activity and PFS following alkylator therapy.

Tumor sample		PFS post alkylator therapy		MGMT (fmol/106 cells)
	N	Failures	Median (mo)	Mean ± SD; [median]; (range)
All alkylator-treated AG	84	60 (71%)	16	5.9 ± 6.7; [4.1]; (< 0.25–32)
Exclude outlier MGMT activitiesa	78	54 (69%)	21	4.4 ± 3.6; [3.6]; (< 0.25–14)
Exclude upper and lower 10% of PFS	68	51 (75%)	16	5.6 ± 6.6; [3.8]; (< 0.25–32)
Without 1p and/or19q deleted AO/AOA	71	54 (76%)	16	6.3 ± 7.1; [4.1]; (< 0.25–32)
Diagnosis
Anaplastic astrocytoma	35	28 (80%)	15	6.2 ± 7.1; [3.2]; (< 0.25–32)
Anaplastic oligodendroglioma	24	17 (71%)	13	5.6 ± 6.4; [4.2]; (< 0.25–32)
Anaplastic oligo-astrocytoma	25	15 (60%)	24	5.8 ± 6.7; [3.8]; (< 0.25–29)
Prior treatment
None and surgery or biopsy onlyb	57	37 (65%)	16	5.8 ± 6.5; [4.1]; (< 0.25–32)
Surgery or biopsy followed by RTc	27	23 (85%)	19	6.2 ± 7.1; [4.1]; (< 0.25–32)
Progression after RT
No	45	27 (60%)	26	4.7 ± 4.2; [3.8]; (< 0.25–23)
Yesd	39	33 (85%)	16	7.3 ± 8.6; [4.3]; (< 0.25–32)
Prior low-grade glioma
No	54	38 (70%)	14	6.7 ± 7.1; [4.8]; (< 0.25–32)
Yes	30	22 (73%)	22	4.6 ± 5.8; [3.1]; (< 0.25–29)
Alkylator therapy
PCV	42	42 (100%)	16	4.8 ± 5.9; [3.1]; (< 0.25–32)
All other alkylatorse	42	28 (67%)	14	7.1 ± 7.3; [4.9]; (< 0.25–32)
None (i.e., RT only)	49	30 (61%)	18	7.3 ± 8.9; [4.0]; (< 0.25–49)

^aLimiting activities to those within the 95% confidence interval for the data eliminated the 6 highest MGMT activities.

^bIncludes 11 tumors previously operated or biopsied.

^cMGMT activity assayed in recurrent tumor re-operated after RT.

^dIncludes the 27 tumors re-operated for recurrence after surgery or biopsy and RT.

^eIncludes 23 tumors treated with chemo-RT, 15 with TMZ and 4 with BCNU.